Ubiquigent extends and expands drug discovery collaboration with Bristol Myers Squibb Kumar Jeetendra | October 26, 2021 Dundee, UK, 26th October 2021 – Ubiquigent Limited (Ubiquigent) today announces the extension and expansion of its long-term collaboration with Bristol Myers Squibb. Under the terms of the agreement, Ubiquigent will provide Bristol Myers Squibb with increased access to its deubiquitylase (DUB) enzyme inhibitor drug discovery platform to provide further support to additional therapeutic areas. …
We are Pioneer Group and Astellas Announce Future Innovator Prize to Help Emerging Biotechs Accelerate Early Drug Discovery and Research Efforts Kumar Jeetendra | October 21, 2021 TOKYO and NOTTINGHAM, UK – 21 October 2021 – Life Science Newswire – Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc, and We are Pioneer Group (WAPG), the UK’s largest ecosystem provider for science and innovation businesses, today announce a new collaborative sponsorship and first of its kind initiative to …
Cipla secures a spot among the top global employers in Forbes’ “World’s Best Employers 2021” list Kumar Jeetendra | October 15, 2021 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) has emerged as the only Indian pharma company to secure a spot in the Forbes “World’s Best Employers 2021” list among the top global employers across 58 countries. Cipla also features as the sole Indian player being featured as a part of …
Xuanzhu and SignalChem Lifesciences Corporation Announce Collaboration and Licensing Agreement for SLC-391 in the Greater China Region Kumar Jeetendra | September 27, 2021 September 27, 2021 – Beijing, China and Richmond, British Columbia, Canada – Life Science Newswire – Sihuan Pharmaceutical Holdings Group Ltd., together with its subsidiaries and SignalChem Lifesciences Corporation today announced that Sihuan Pharmaceutical Holdings Group Ltd subsidiary company Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu”) and SignalChem Lifesciences Corporation (“SignalChem”) have entered into an exclusive collaboration …
Takara Bio Europe AB and Boston IVF Fertility Center Announce Partnership to Enable the Derivation of Clinical-grade hES cell lines for Cell Therapy Applications Kumar Jeetendra | September 20, 2021 September 20, 2021 –– Takara Bio Europe AB (TBEAB) is proud to officially announce a partnership with the Boston IVF Fertility Center (Boston IVF) headquartered in Waltham, Massachusetts, USA. This partnership gives TBEAB access to discarded starting material for the derivation of clinical-grade hES cell lines for cell therapy research. “When we set off to …
IBM Research and Arctoris accelerate closed loop drug discovery with AI and Cloud Kumar Jeetendra | September 13, 2021 Oxford and Zurich – 13 September 2021 – Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry. Representing chemical reactions via SMILES …
ENPICOM introduces a powerful liability prediction solution to de-risk antibody development Kumar Jeetendra | September 7, 2021 The Netherlands – September 7, 2021 – ENPICOM, an innovative bioinformatics software company, announced today at the Biologics UK conference new IGX Platform capabilities to accurately annotate exposed liabilities, perform structural modeling of antibodies at scale, and determine developability profiles using customizable penalties. This major development allows researchers to improve their candidate selection by making …
Apollo Proton Cancer Centre Launches India’s First Video Newsletter Kumar Jeetendra | September 6, 2021 Chennai, 6th September 2021: Apollo Proton Cancer Centre (APCC), the first Proton Therapy Centre in South Asia & the Middle East, launched India’s first video newsletter – PRONEWS. Aimed at reaching readers with the latest in Cancer care and treatment, PRONEWS will be a quarterly compilation that will educate, empower and elevate the knowledge of …
After a successful winter initiative, CytoSMART Research Grant project resumes again Kumar Jeetendra | September 6, 2021 Eindhoven, The Netherlands – CytoSMART Technologies today opened the application of CytoSMART Research Grant for 2021 Autumn. The CytoSMART Research Grant is an initiative to help motivated students and researchers improve their project’s quality. The grant offers one of the CytoSMART live-cell imaging devices that can be used for research purposes for a specified period. …
Magnetic Bead Based Nucleic Acid Extraction: Machines as per your need Kumar Jeetendra | September 2, 2021 Going by the famous saying, ‘Change is the only constant’, HiGenoMB®, the molecular biology division of HiMedia Laboratories has been developing extraction kits and platforms for the last 15 years. Diagnostic tests lay the foundation to taking the right medical decisions. Molecular Diagnostics stands as the most dynamic and flourishing area of diagnostics. A recent …
Viedoc Technologies achieves certification to ISO/IEC 27001:2013 Kumar Jeetendra | August 31, 2021 Uppsala, Sweden – August 24, 2021 –– Viedoc Technologies was recently presented with its ISO/IEC 27001:2013 certificate affirming that the company’s operation globally, adheres to the internationally recognized standard for information security management. The certification ensures clients worldwide that Viedoc has implemented processes and procedures for implementing, maintaining, and continually improving its information security management …
IntraBio Reports Statistically Significant and Clinically Meaningful Improvements in the Use of IB1001 For Treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease) Kumar Jeetendra | August 27, 2021 OXFORD, UK – August 19, 2021 – Life Science Newswire – IntraBio Inc today announced positive data from its multinational clinical trial of IB1001 (N-acetyl-L-leucine) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff disease). IB1001 demonstrated a statistically significant and clinically meaningful improvement in symptoms, functioning, and quality of life in both the primary …
